Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)

Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited) FORT WORTH, TX, November 12, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused

Event · Earnings
Also in this documentGuidance · lower · $110M–$115M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 12, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SMTI
Bearish
high confidence
Mentioned
$SMTI
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SMTIBearishMed
01

Why it matters

The earnings release provides fresh financial data and merger status, offering traders new information to assess risk.

02

Market read

New earnings numbers and merger progress create a short‑term trading catalyst for SMTI.

03

What to watch

Strong gross margin stability (93%) and continued product demand may support longer‑term valuation.

Relevance 7/10Novelty 7/10Timing: post‑market filing

Background

Sanara MedTech filed a Form 8‑K reporting its Q3 2026 results and progress on a pending merger with MiMedx.

Company-level read

Ticker impact

$SMTIBearishHigh confidence
Context

Q3 2026 earnings release showing 8% revenue growth but a net loss of $1.3M and pending merger with MiMedx.

Expected impact

likely pressure as the market prices in the loss and merger risk

Evidence & confidence

Operating income fell sharply and legal expenses rose, while the pending merger adds execution risk.

Market effects

Medical‑technology sector sees modest revenue growth but heightened cost pressure.

US med‑tech stocks may face short‑term downside on earnings miss.

Limited; impact confined to niche surgical‑device niche.

Counterpoint

If the merger closes, synergies could unlock upside despite the short‑term loss.

Key entities

  • Sanara MedTech Inc.

    Medical‑technology firm reporting Q3 2026 results.

  • MiMedx Group, Inc.

    Potential acquirer in a pending merger.

Related articles

$SMTIMedAI 8/10

MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months

The FTC issued a Second Request for more information on MiMedx's (MDXG) acquisition of Sanara (SMTI), delaying the merger beyond the year-end target. SMTI shares fell 5.5%, dropping below their 50-day moving average, while MDXG shares declined 2.8%. The deal, valued at $35 per share, aims to create a larger regenerative medicine company with $400M revenue expected in FY2027.

$SMTIMedAI 8/10

Sanara MedTech Inc., a Texas corporation, entered into an Agreement and Plan of Merger with MiMedx Group, Inc., a Florida corporation, and Mustang Merger…

Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously announced, Sanara MedTech Inc., a Texas corporation (the “Company” or “Sanara”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with MiMedx Group, Inc., a Florida corporation (“MiMedx”), and Mustang Merger Sub, Inc., a

$SMTIMedAI 8/10

Sanara MedTech Q2 Results: Sales Rise 9% YoY, EPS Misses Estimate

Sanara MedTech (NASDAQ: SMTI) reported Q2 EPS of $(0.05), missing the $0.02 consensus, and sales of $28.137 million, up 8.93% YoY but below the $28.950 million estimate. The article also says Kahn Swick & Foti opened an investigation into SMTI’s proposed acquisition by MiMedx (NASDAQ: MDXG), valuing the deal at about $350 million ($35.00 per SMTI share).